supplemental Table 1: breakpoint and patient information
# UPNbp upstreamMLLMLLT1P/ATypeCenter
of MLLT1 Ex 2
______
1P03-167Intron 9Intron 3PALLRotterdam
2P05-435Intron 11Intron 6AAMLParis
3P05-414674Intron 9Intron 1AALLVienna
4P04-359790Intron 9Intron 1AALLBerlin
5P05-6041200Intron 10Intron 1PALLKiel
6P05-5281434Intron 9Intron 1AALLBerlin
7P03-0732360Intron 11Intron 1PALLHeidelberg
8P05-4123234Intron 10Intron 1AAMLParis
9P05-5793353Intron 11Intron 1PAMLParis
10P04-3043385Intron 11Intron 1AALLBerlin
11P05-5183589Intron 9Intron 1PAMLParis
12P05-4013725Intron 11Intron 1PALLRotterdam
13P05-3874730Intron 9Intron 1PALLVienna
14P05-5604986Intron 10Intron 1AALLBerlin
15P03-2335619Intron 11Intron 1AALLBerlin
16P05-5745869Exon 11Intron 1AALLBerlin
17P05-3856529Intron 11Intron 1AALLBerlin
18P05-5517375Intron 10Intron 1AALLBerlin
19P05-5617992Intron 11Intron 1AALLBerlin
20P05-5408348Intron 11Intron 1AALLBerlin
21P05-46511648Intron 11PALLLublin
22P04-36211666Intron 11PALLCatania
23P05-52512137Intron 11PALLPadua
24P05-58012456Intron 11AALLBerlin
25P04-34314175Intron 10PALLBerlin
26P04-26918273Intron 11PALLCatania
27P04-32418436Intron 11PALLLondon
28P05-59122440Intron 11AALLBerlin
2997252924002Intron 11PALLVienna
3091082325786Intron 11PALLVienna
31P04-30828531Intron 11PALLLublin
32P05-53629629Intron 10PALLPrague
33P05-59230211Intron 11AALLBerlin
34P05-41330763Intron 11PALLParis
35P05-60531011Intron 11PALLKiel
36P04-36032559Intron 11PALLCatania
37P05-55034345Intron 9AALLBerlin
38P04-30334664Intron 11AALLBerlin
39P05-52434790Exon 11PALLPadua
4094242635107Intron 10PALLVienna
______
UPN, localisation of genomic breakpoints, involved MLL sequences, involved MLLT1 sequences, adult (A) or pediatric patient (P), disease phenotype and study centers are given for each t(11;19)(q23;p13.3) patient.
supplemental Table 2: Chromosomal fusion sites
UPNfusion sequence
______
P03-167ACGAGCCCACAAGGTCTAGGCTGCAGTG•AG•GGGAGTGTGGCTGTTTGGGGCGGTAAAAC
P05-435CACGCCTGTAATCCCAGTACTTTGGGA•GGCT•TTCGTGGGGACCCTTCTGCAGGGTGGAG
P05-414GAGGCCAGCAGTTCAAGACCAGCCTGGGCA•TGGCCTCTGCCTTCTTCTTGGGAACCTCCC
P04-359GGCTCCCCTCGGCTGAGATAGAAGGATT•G•CCTGAGCTGCCTTGTATTTCAGAGCAAAGT
P05-604ACATTCCTATCCATCCTGAGCAGTATCA•CA•GAGCGTCTCAGACTTGAGGAAATACACGC
P05-528CTGCACTCCAGCTTGGGTGACACCGAGA•TT•CGAGCGTCTCAGACTTGAGGAAATACACG
P03-073GGCAGCGGATCACAAGGTCAGGAGATCCAG•TATTTCTTTTGTCTCCGGCCTGATCCCAGG
P05-412TTCAGTGATCATAAAGTATATTGAGTGTCA•GGAACCTTCCTGTTTACTTTGGCCACTGCG
P05-579TCAAAAAAATAAATAAATAAAAATTAAAA•C•CAAGTCTGGGGTGTGTCCTTAACAGTGGG
P04-304ATACTTCTATCTTCCCATGTTCTTACTATA•CCGAACTTCGCATCTGTTGGCCAAGTCTGG
P05-518TGCGTGTAGTCCCAGGTACTCAGGAGGCTG•GCTGTGCTAATAAATTATCATGACCTGACA
P05-401TTCCCATAGCTCTTTGTTTATACCACT•CTTA•ACCTCTGCAGCCAGGCACCCTTCCTAGA
P05-387GGGGGTTTTATTGGGTCTCATGTTGCCGTC•TAGTGAGCTATGATTGTACCACTGCAGTCC
P05-560AAAGAGGAAATCAGCACCAACTGGGGGAA•GG•ATTGAGTGCCTTCTCATCGCTTTGTCAT
P03-233TGTGGAAATGCAGGCTCAGAAGTCCTACCA•TATAGTTTGTGTATTGCCAAGTCTGTTGTG
P05-574GAGGGGACTGGGACGTGACAAGGATAAGGC•AGAGGTAAGGCATCCTGCTTCTTTGTACCC
P05-385AGATTTTAGGAAGGAATCTGCTATTAGAG•T•TGGACCCAAAGTCTGATTCTAGCTTCCCC
P05-551CTGCAGAACATACATAATGAAACATTCCT•GA•TGCTGGCGCCACTGAAGTGGCACTGTCT
P05-561GAATCTCCCGCAGTGTCCAATACTGT•CCCTAATA•TCCCCAGACCTTTGAGTCACTGATG
P05-540TTATTTTGTTACTTTCTATTTCCACTGG•TAT•CTCCACCCATCCCCTACCTGGACCTGAG
P05-465TAAATAGGAAGCAGTAGTTTGTCATTTATA•TGGGTATATACCCAGTAATGGGATTGCTGG
P04-362CTTTAGAGTTTTTATCTGGACTTACTTTC•AT•ATCTAGAAAACAATCTGGAAGGATTCAC
P05-525GCTTGCAGTGAGCCGAGATCGCCCCACTGC•TATGCAGGTTTGTTACATAGGTAAACGTGT
P05-580TTAGGAAGGAATCTGCTATTAGAGTAGCA•TG•ATCTCCTGGGTTCAAGCGATCCTCCTGC
P04-343TATCTAAAAATTTGAGAACAAGTTGCAG•ACA•AAAAAAAGAAAATACAAAAATTAGCTGA
P04-269TTCATTTACTAAGCAAATATTCTCTTAG•AAC•AAGGCCATTAGGACAGCTGAATCAATCC
P04-324CAATCTCACA•GG•CTGTTGGC/-GNA15-INSERT/-ATTAAAAGA•GGC•AGTTGAGAC
P05-591ACATAAATTATTTTTCTGTGGATGAAATT•C•CTTTTGAACTCATGGAGGGGCAGAGAATA
972529GTCTACTGTATCCTCTTTTCCGTCTTAAT•A•GTTAGAGTTCTTTTATATAAACATCACAC
910823TTTTCCATCCAAAGTTGTGTAATTGTAA•AAC•AGCCGGGCGTGGTGGCTCACGCCTGTAA
P04-308TATTATCTGATCTATAGGCCTTATTTAGG•T•ATACTTTGTATCTGTTATACAATTTTTCA
P05-536ACTTTAGTACTCTGAATCTCCCGCAGTGTC•ACCAGCCTGGCCGACATGGTGAAACCCCAT
P05-592GAAGAATCGCTTGAACCCAATTGGCGGAGG•AATAAAAATTAAAACAATTAAAAAAATAAA
P05-413CATGGGTGGGAGCGGCCACCAGGAGGGCT•AG•ACCTTACAACTGTTTCGTATATTACAGA
P05-605CAGATCAGCCTGGGCAACATGGTTAAACCC•TTAAAGTATATATCTAGAAAACAATCTGGA
P04-360CTCCAGCCTGGGCGATACAGCGAGACTGC•GT•TCATTTCAATATTGCTCATAATAATAAA
P05-550GCAAGACCCTGTCTTTATTTAAACAAAA•TCC•TTTGCCCATCCAGTAATTTATCCAACGA
P04-303GTTTTGTTGGTATTTAGCAGGTACTATTCC•TCATCCACCCACCCTTTAATTCATCTACCC
P05-524ATGGGAGGCTTAGGAATCTTGACTTCTGT•CC•AATGAATGTGTGTGAAGTCCTTAGCATA
942426CAAAGACTTTAAATAAAGAAAATGCTACTA•GTTCACAGCTGAGAACAGCAGAGTCCCAGA
______
UPN and breakpoint sequences are given for each patient. Mini-direct-repeats are underlined; Filler-DNA is shown in bold (Filler DNA = sequences not derived from chromosome 11 or 19); for patient P04-324, a 848 bp insertion was identified at the breakpoint that derived from the GNA15 gene located about 3.1 Mbp telomeric to the MLLT1 gene at chromosome 19p13.3. Chromosome 19 sequences are shown in italics.